The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losses to Follow-Up, Noncompliance, and Stratification
Abstract
When designing a clinical trial to test the equality of survival distributions for two treatment groups, the usual assumptions are exponential survival, uniform patient entry, full compliance, and censoring only administratively at the end of the trial. Various authors have presented methods for estimation of sample size or power under these assumptions, some of which allow for an R-year accrual period with T total years of study, T greater than R. The method of Lachin (1981, Controlled Clinical Trials 2, 93-113) is extended to allow for cases where patients enter the trial in a nonuniform manner over time, patients may exit from the trial due to loss to follow-up (other than administrative), other patients may continue follow-up although failing to comply with the treatment regimen, and a stratified analysis may be planned according to one or more prognostic covariates.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Continuous Univariate Distributions.
Omori, Y., Johnson, N. L., Kotz, S., & Balakrishnan, N. (1995) · Journal of the American Statistical Association · doi:10.2307/2291547 · Cited by 9,084
Introduction to sample size determination and power analysis for clinical trials
Lachin, J. M. (1981) · Controlled Clinical Trials · doi:10.1016/0197-2456(81)90001-5 · Cited by 1,012
Self-citationTables of the number of patients required in clinical trials using the logrank test
Freedman, L. S. (1982) · Statistics in Medicine · doi:10.1002/sim.4780010204 · Cited by 718
Introduction to Stochastic Processes in Biostatistics
Bartlett, M. S., & Chiang, C. L. (1969) · Revue de l'Institut International de Statistique / Review of the International Statistical Institute · doi:10.2307/1402301 · Cited by 681
Survival Distributions: Reliability Applications in the Biomedical Sciences
(1978) · Food and Cosmetics Toxicology · doi:10.1016/s0015-6264(78)80019-4 · Cited by 521
The asymptotic properties of nonparametric tests for comparing survival distributions
SCHOENFELD, D. (1981) · Biometrika · doi:10.1093/biomet/68.1.316 · Cited by 500
Schoenfeld, D. A., & Richter, J. R. (1982) · Biometrics · doi:10.2307/2530299 · Cited by 354
Planning the size and duration of a clinical trial studying the time to some critical event
George, S. L., & Desu, M. M. (1974) · Journal of Chronic Diseases · doi:10.1016/0021-9681(74)90004-6 · Cited by 279
Rubinstein, L. V., Gail, M. H., & Santner, T. J. (1981) · Journal of Chronic Diseases · doi:10.1016/0021-9681(81)90007-2 · Cited by 267
Approaches to sample size estimation in the design of clinical trials—a review
Donner, A. (1984) · Statistics in Medicine · doi:10.1002/sim.4780030302 · Cited by 250
Sample sizes for medical trials with special reference to long-term therapy
Halperin, M., Rogot, E., Gurian, J. M., & Ederer, F. (1968) · Journal of Chronic Diseases · doi:10.1016/0021-9681(68)90082-9 · Cited by 135
Some Applications of Exponential Ordered Scores
Cox, D. R. (1964) · Journal of the Royal Statistical Society Series B (Statistical Methodology) · doi:10.1111/j.2517-6161.1964.tb00544.x · Cited by 92
Sample size and power determination for stratified clinical trials
Bernstein, D., & Lagakos, S. W. (1978) · Journal of Statistical Computation and Simulation · doi:10.1080/00949657808810249 · Cited by 90
Sample sizes for long-term medical trial with time-dependent dropout and event rates
Wu, M. C., Fisher, M. R., & DeMets, D. L. (1980) · Controlled Clinical Trials · doi:10.1016/0197-2456(80)90014-8 · Cited by 72
Sample size requirements for comparing time-to-failure among k treatment groups
Makuch, R., & Simon, R. M. (1982) · Journal of Chronic Diseases · doi:10.1016/0021-9681(82)90051-0 · Cited by 62
Lachin, J. M., Marks, J. W., Schoenfield, L. J., Tyor, M. P., Bennett, P. H., Grundy, S. M., Hardison, W. G. M., Shaw, L., Thistle, J. L., Vlahcevic, Z. R., et al. (1981) · Controlled Clinical Trials · doi:10.1016/0197-2456(81)90012-x · Cited by 55
Self-citationSchork, M. A., & Remington, R. D. (1967) · Journal of Chronic Diseases · doi:10.1016/0021-9681(67)90005-7 · Cited by 53
The Efficiency of the Proportions Test and the Logrank Test for Censored Survival Data
Cuzick, J. M. (1982) · Biometrics · doi:10.2307/2529884 · Cited by 49
Gail, M. H. (1985) · Controlled Clinical Trials · doi:10.1016/0197-2456(85)90116-3 · Cited by 40
Cited by
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804710 · Cited by 2,397
Power and sample size calculations
Dupont, W. D., & Plummer, W. D. (1990) · Controlled Clinical Trials · doi:10.1016/0197-2456(90)90005-m · Cited by 2,092
Prednisone, Azathioprine, and N -Acetylcysteine for Pulmonary Fibrosis
The Idiopathic Pulmonary Fibrosis Clinical Research Network (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113354 · Cited by 1,621
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809798 · Cited by 1,317
Metadata
- Authors
- Lachin, J. M., & Foulkes, M. A.
- Venue
- Biometrics
- Publisher
- JSTOR
- Published
- 1986-09
- Volume
- 42
- Issue
- 3
- Pages
- 507
- ISSN
- 0006-341X (ISSN-L)
- OpenAlex
- W2007343138
- Cited by
- 400
- References
- 20
- FWCI
- 3.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.